Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Oncology Institute (TOI) Depreciation & Amortization - Total (2021 - 2025)

Oncology Institute's Depreciation & Amortization - Total history spans 5 years, with the latest figure at $915000.0 for Q4 2025.

  • For Q4 2025, Depreciation & Amortization - Total fell 1.93% year-over-year to $915000.0; the TTM value through Dec 2025 reached $4.0 million, up 24.15%, while the annual FY2025 figure was $4.0 million, 24.15% up from the prior year.
  • Depreciation & Amortization - Total reached $915000.0 in Q4 2025 per TOI's latest filing, down from $1.0 million in the prior quarter.
  • In the past five years, Depreciation & Amortization - Total ranged from a high of $1.0 million in Q2 2025 to a low of $165000.0 in Q1 2021.
  • Average Depreciation & Amortization - Total over 5 years is $618650.0, with a median of $658000.0 recorded in 2023.
  • Peak YoY movement for Depreciation & Amortization - Total: soared 132.57% in 2023, then dropped 12.47% in 2024.
  • A 5-year view of Depreciation & Amortization - Total shows it stood at $263000.0 in 2021, then soared by 74.9% to $460000.0 in 2022, then soared by 75.65% to $808000.0 in 2023, then grew by 15.47% to $933000.0 in 2024, then dropped by 1.93% to $915000.0 in 2025.
  • Per Business Quant, the three most recent readings for TOI's Depreciation & Amortization - Total are $915000.0 (Q4 2025), $1.0 million (Q3 2025), and $1.0 million (Q2 2025).